Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Laboratoires Thea clinical trials
Part of Théa Holding SAS.
The registry lists 64 studies whose lead sponsor is Laboratoires Thea. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Laboratoires Thea studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Laboratoires Thea.
- Laboratoires Thea64 studiesSame company
Something wrong?
Focus areas
Conditions Laboratoires Thea leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 64. Browse all 64 →
- Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)RecruitingNCT06891443Phase 3
- Evaluation of Corneal Endothelium Health Following Articaine Ophthalmic Solution AdministrationNot yet recruitingNCT07838129Phase 4
- Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneNot yet recruitingNCT07796646Phase 2
- Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®RecruitingNCT07206628
- Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid SurgeryRecruitingNCT07234292
- A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal KeratoconjunctivitisRecruitingNCT07169695Phase 2
- Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia ProgressionRecruitingNCT07522242Phase 2
- New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry EyeCompletedNCT06903741Not applicable
- A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS StudyCompletedNCT07234318
- Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneActive, not recruitingNCT06627179Phase 2
- Performance and Safety of T2769 in DEDCompletedNCT05965778Not applicable
- Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT06394973Phase 2
- Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.CompletedNCT06375499Not applicable
- Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye DiseaseCompletedNCT07007702
- Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.CompletedNCT05931861Not applicable
- Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneCompletedNCT03140969Phase 1/2
- Extension Study to Study PQ-110-001 (NCT03140969)TerminatedNCT03913130Phase 1/2
- Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)TerminatedNCT05176717Phase 2/3
- An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis PigmentosaTerminatedNCT05085964Phase 2
- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT05397600Phase 3
- Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)TerminatedNCT05158296Phase 2/3
- Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.Active, not recruitingNCT05389267Phase 1/2
- Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT01494753Phase 2
- Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT03825380Phase 3
- Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy VolunteersCompletedNCT05729594Phase 1
- Efficacy of T2259 in DEDCompletedNCT03874429Not applicable
- Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.CompletedNCT04898387Phase 3
- Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy VolunteersCompletedNCT05622435Not applicable
- Efficacy, Safety of T2769 in Dry Eye DiseaseCompletedNCT03830359Not applicable
- Macula Evolution in Patients With AMD Taking Oral Food SupplementationCompletedNCT04778436Not applicable
- Gastrointestinal Tolerance Assessment of T2309CompletedNCT04596605Not applicable
- Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of GlaucomaCompletedNCT04552964Not applicable
- Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily TreatmentCompletedNCT04803240
- Efficacy and Tolerability of Blephademodex WipesCompletedNCT04780165Not applicable
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit DoseCompletedNCT02017327Phase 4
- Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal UlcerCompletedNCT01794312Phase 3
- Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated CrosslinkingCompletedNCT02979054Not applicable
- Efficacy and Safety of T2762 and Vismed® in Dry Eye SyndromeCompletedNCT02023268Phase 3
- Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT02278614Phase 3
- Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.CompletedNCT01155219Phase 4
- Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye SyndromeTerminatedNCT02617095Not applicable
- Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye SyndromeCompletedNCT01568593Phase 3
- Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops VialsWithdrawnNCT01546012Not applicable
- Management of Eyelid Disorders by Ophthalmologists in Usual Medical PracticeCompletedNCT01552174
- Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT01156012Phase 3
- Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract SurgeryCompletedNCT02101359Phase 3
- Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With BlepharitisCompletedNCT01089608Phase 2
- Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.CompletedNCT01155999Phase 3
- Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface DiseasesCompletedNCT01189474Phase 4
- Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic ConjunctivitisCompletedNCT01344083Phase 2